- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β cell. Abstract A specific
site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas
leading to closure of the potassium channels and subsequent opening of calcium ... Cited by 87 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org NN Zammitt, BM Frier - Diabetes Care, 2005 - Am Diabetes Assoc The importance of strict glycemic control to limit the risk of diabetic vascular complications is
indisputable, but many barriers obstruct its attainment. Hypoglycemia is recognized to be a major
limitation in achieving good control in type 1 diabetes (1) but has been considered to be a ... Cited by 89 - Related articles - All 6 versions
- ►diabetesjournals.org ML Evans, RJ McCrimmon, DE Flanagan, T Keshavarz, … - Diabetes, 2004 - Am Diabetes Assoc It has been postulated that specialized glucose-sensing neurons in the ventromedial hypothalamus
(VMH) are able to detect falling blood glucose and trigger the release of counterregulatory hormones
during hypoglycemia. The molecular mechanisms used by glucose-sensing neurons are ... Cited by 74 - Related articles - BL Direct - All 5 versions
- ►endojournals.org J Gromada, I Franklin, CB Wollheim - Endocrine reviews, 2007 - Endocrine Soc Glucagon, a hormone secreted from the -cells of the endocrine pancreas, is critical for blood
glucose homeostasis. It is the major counterpart to insulin and is released during hypoglycemia
to induce hepatic glucose output. The control of glucagon secretion is multifactorial and ... Cited by 61 - Related articles - BL Direct - All 4 versions
DSH Bell - The American journal of medicine, 2004 - Elsevier Treatment options for type 2 diabetes mellitus currently consist of insulin sensitizers, α-glucosidase
inhibitors, secretagogues, and insulin. However, the emphasis on initial therapy has been shifting
from secretagogues and α-glucosidase inhibitors to insulin sensitizers such as metformin ... Cited by 33 - Related articles - All 8 versions
- ►adisonline.com [PDF] AD Mooradian - Treatments in Endocrinology, 2004 - ingentaconnect.com Type 2 diabetes mellitus emerges as a result of multiple pathophysiologic changes. If the pharmacotherapy
of Abstract type 2 diabetes should be tailored to the underlying pathophysiology, it would be
necessary to use a combination of agents with complementary mechanisms of action. The ... Cited by 7 - Related articles - BL Direct - All 4 versions
- ►endojournals.org T Ostergard, KB Degn, MA Gall, RD Carr, JD … - Journal of Clinical …, 2004 - Endocrine Soc In vitro data have recently suggested that sulfonylureas (SUs) enhance GH secretion by modulating
the effects of GHRH and somatostatin in pituitary cells. The present study was undertaken to
explore in more detail a possible influence of a single dose of SU (glibenclamide) and a ... Cited by 4 - Related articles - BL Direct - All 5 versions
E Szoke, NR Gosmanov, JC Sinkin, A Nihalani, AB … - Metabolism, 2006 - Elsevier Severe hypoglycemia, the most serious side effect of sulfonylurea therapy, has been reported
to occur more frequently with glyburide than glimepiride. The present studies were undertaken
to test the hypothesis that a differential effect on glucagon secretion may be involved. We ... Cited by 4 - Related articles - All 16 versions
RR Gonzalez, S Zweig, J Rao, R Block, LW Greene - Endocrine Practice, 2007 - AACE Sulfonylureas are widely used in patients with type 2 diabetes. Although adverse effects are
reportedly rare, occurring in approximately 4% of patients taking these drugs, hypoglycemia
is the most common consequence, and it may be prolonged and severe, leading to coma ... Cited by 1 - Related articles - BL Direct - All 3 versions
[CITATION] 11 Hypoglycaemia in Type 2 Diabetes and in Elderly People
